Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea/Heart Failure
Author(s): Tarek Bekfani , Joseph D Abraham , William T Abraham Added: 8 months ago

Heart Failure
ACC 26: STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion
Author(s): Navin K Kapur Added: 1 month ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,… View more

Intervention

Heart Failure
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Author(s): Dung Viet Nguyen , Hoai Thi Thu Nguyen Added: 6 months ago

Heart Failure
PAP Therapies for HF: What Do the Trials Tell Us?
Author(s): Jan Pec , Michael Arzt Added: 5 months ago

Guidelines & Statements

Heart Failure
ACC 26 Highlights: STEMI-DTU, GOFRESH, and HI-PEITHO
Author(s): Anuradha Lala Added: 1 month ago
ACC.26 - Dr Anuradha Lala-Trindade (Mount Sinai, New York, NY, US) provides her expert analysis of the most impactful late-breaking clinical trials presented at ACC.26, highlighting studies with the potential to influence clinical practice and shape future cardiovascular care. Key Late-Breaking Trials Discussed0:16 – STEMI-DTU: Primary Left Ventricular Unloading in Anterior ST-Segment Elevation… View more

Intervention

Prevention & Chronic Conditions
Lipoprotein(a): A Risk Factor and Biomarker in Heart Failure
Author(s): Anna Kowalczys , Joanna Marlęga-Linert , Marcin Gruchała , et al Added: 2 weeks ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Author(s): Silas Ramos Furquim , Maria Tereza Sampaio de Sousa Lira , Deborah de Sá Pereira Belfort , et al Added: 4 months ago

Guidelines & Statements

Heart Failure
VICTOR Trial: Vericiguat Shows No Benefit for Primary Endpoint in Stable HFrEF
Added: 8 months ago Source:  Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide… View more

Guidelines & Statements

Heart Failure
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 9 months ago

Heart Failure
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic